Echocardiographic Changes after Treatment with Anthracyclines in Children

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Pediatrics, Cardiac Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Resident, Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran

3 Assistant Professor, Department of Pediatrics, Hematology Research Center, Shiraz Universi

Abstract

Background: In this study, we evaluated systolic and diastolic changes over time after treatment with anthracyclines in children.Methods: In this study, 25 patients aged 1-17.5 years were assessed. Echocardiography was performed just after starting chemotherapy, 6 months and one year after stating of anthracyclines. Echocardiography results of 25 healthy aged matched children were recorded as the control group.Findings: The average anthracycline dose was 371 mg/m2 (range: 100-690 mg/m2) before the third echocardiography. M-mode echocardiography did not show statistically significant differences. However, Doppler and pulse tissue Doppler showed statistically significant changes between the first echocardiography, and those performed six and one year later (P < 0.05).In tissue Doppler echocardiogram statistically significant changes were observed in systolic wave of septum, atrial wave of anterior wall, early and late diastolic wave of lateral tricuspid and mitral valve. There was a statistically significant correlation between wave changes and the anthracycline dose received. Conclusion: According to our study, tissue Doppler echocardiography can detect early cardiac abnormalities which cannot be detected by two-dimensional echocardiography. Such changes are dose-dependent.

Keywords

References

  1. Kadan-lottick NS. Epidemiology of childhood and adolescent cancer. In: Kliegman R, Behrman RE, Nelson WE, Jenson HB, editors. Nelson textbook of pediatrics.Philadelphia: Saunders; 2007.
  2. Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 2011; 32(3): 342-53.
  3. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25(4 Suppl 10): 72-85.
  4. Steinhers LJ. Cardiac toxicity. In: DeVita VTJ, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams &Wilkins; 2001.
  5. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 144(1): 3-15.
  6. Sengupta PP, Mohan JC, Pandian NG. Tissue Doppler echocardiography: principles and applications. Indian Heart J 2002; 54(4): 368-78.
  7. Speyer JI, Freibarg RS. Cardiac complication. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical Oncology. 3rd ed. 2000.
  8. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7(2): 141-6.
  9. Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniels O. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol 2000; 26(7): 1099-108.
  10. Nagy AC, Cserep Z, Tolnay E, Nagykalnai T, Forster T. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res 2008; 14(1): 69-77.
  11. Hong-wen F, Xin-fang W, Ming-xing X, Ya-le H. Tissue Doppler echocardiography detecting early myocardial relaxation abnormality in Adriamycin-induced cardiomyopathy rabbits. Journal of China Clinic Medical Imaging 2006;1: 28-31.
  12. Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19(7): 1926-34.
  13. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332(26): 1738-43.
  14. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62(2): 200-8.
  15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-79.
  16. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16(2): 545-50.
  17. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13(6): 819-29.
  18. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324(12): 808-15.
Journal of Isfahan Medical School
Volume 29, Issue 170 - Serial Number 170
November and December 2012
Pages 2705-2714

Files

History

  • Receive Date: 07 May 2011
  • Revise Date: 02 June 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics